Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

JCR Pharmaceuticals Management

Management Kriterienprüfungen 2/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Shin Ashida

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	19yrs
Eigentum des Geschäftsführers	0.008%
Durchschnittliche Amtszeit des Managements	7yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	4.4yrs

Jüngste Management Updates

Recent updates

JCR Pharmaceuticals Co., Ltd. (TSE:4552) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely

May 22

JCR Pharmaceuticals (TSE:4552) Is Due To Pay A Dividend Of ¥10.00

Mar 18

JCR Pharmaceuticals (TSE:4552) Has Affirmed Its Dividend Of ¥10.00

Feb 29

Geschäftsführer

Shin Ashida (81 yo)

19yrs

Amtszeit

Mr. Shin Ashida has been the Chairman of JCR Pharmaceuticals Co., Ltd. since July 1995 and its Chief Executive Officer since June 2005. Mr. Ashida has been the President of JCR Pharmaceuticals Co., Ltd., s...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Shin Ashida	Chairman	19yrs	keine Daten	0.0083% ¥ 5.8m
Yoshihiro Ota	Director of Accounting Department & Corporate Strategy Department (Finance)	no data	keine Daten	keine Daten
Yutaka Honda	Senior Corporate Officer	8yrs	keine Daten	keine Daten
Hiroyuki Fukuya	Director of Legal Affairs Department - Administration Division	no data	keine Daten	keine Daten
Toru Ashida	Senior VP of Sales & Administration	4.2yrs	keine Daten	0.21% ¥ 145.8m
Ryutaro Makino	Director of Marketing Dept. & Group Manager of Product Planning - Marketing Dept. for Sales Div.	3.7yrs	keine Daten	keine Daten
Katsuya Nishino	Executive Vice President	13.9yrs	keine Daten	keine Daten
Hiroshi Yoshimoto	Senior Advisor	13.1yrs	keine Daten	keine Daten
Takayo Egawa	Corporate Officer & Director of International Affairs Office	no data	keine Daten	keine Daten
Hiroyuki Sonoda	VP of Research & Corporate Strategy	6yrs	keine Daten	0.0015% ¥ 1.0m
Kazunori Tanizawa	Corporate Officer & Executive Director of Development Division	no data	keine Daten	keine Daten
Mathias Schmidt	VP of Clinical Development	4yrs	keine Daten	keine Daten

7.0yrs

Durchschnittliche Betriebszugehörigkeit

62yo

Durchschnittliches Alter

Erfahrenes Management: Das Managementteam von 4552 ist erfahren und erfahren (durchschnittliche Amtszeit: 6.9 Jahre).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Shin Ashida	Chairman	19yrs	keine Daten	0.0083% ¥ 5.8m
Toru Ashida	Senior VP of Sales & Administration	no data	keine Daten	0.21% ¥ 145.8m
Hiroyuki Sonoda	VP of Research & Corporate Strategy	4.4yrs	keine Daten	0.0015% ¥ 1.0m
Mathias Schmidt	VP of Clinical Development	4.4yrs	keine Daten	keine Daten
Yoshio Hiyama	Sr. Exec. Director	3yrs	keine Daten	0.0013% ¥ 882.9k
Marc Dunoyer	Independent Outside Director	1.4yrs	keine Daten	keine Daten
Philippe Fauchet	Independent Outside Director	no data	keine Daten	keine Daten
Toshihide Yoda	Independent Outside Director	no data	keine Daten	keine Daten
Toshihiro Ishikiriyama	Independent Outside Director	9yrs	keine Daten	0.0064% ¥ 4.5m
Yutaka Atomi	Independent Outside Director	2yrs	keine Daten	keine Daten
Takashi Suetsuna	Independent Outside Director	no data	keine Daten	keine Daten
Yuko Hayashi	Independent Outside Director	no data	keine Daten	keine Daten

4.4yrs

Durchschnittliche Betriebszugehörigkeit

65.5yo

Durchschnittliches Alter

Erfahrener Vorstand: 4552Die Vorstandsmitglieder gelten als erfahren (4.3 Jahre durchschnittliche Amtszeit).

JCR Pharmaceuticals Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

JCR Pharmaceuticals Co., Ltd., Annual General Meeting, Jun 26, 2024

JCR Pharmaceuticals Co., Ltd. Announces Organizational and Personnel Changes

Jcr Pharmaceuticals Co., Ltd. Announces Executive Changes

JCR Pharmaceuticals Co., Ltd. Appoints Yoh Ito as Senior Corporate Officer

JCR Pharmaceuticals Co., Ltd. Announces Executive Changes

JCR Pharmaceuticals Co., Ltd. Appoints Pascal Yoshida as Senior Director, Head of Medical Affairs Unit

Recent updates

JCR Pharmaceuticals Co., Ltd. to Report Q1, 2025 Results on Jul 30, 2024

Price target decreased by 10% to JP¥1,314

JCR Pharmaceuticals Co., Ltd. (TSE:4552) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely

Investor sentiment deteriorates as stock falls 22%

Full year 2024 earnings: EPS and revenues miss analyst expectations

JCR Pharmaceuticals Co., Ltd., Annual General Meeting, Jun 26, 2024

JCR Pharmaceuticals Co., Ltd. Announces Dividend for the Year Ended March 31, 2024, Payable on June 27, 2024

Upcoming dividend of JP¥10.00 per share

JCR Pharmaceuticals Co., Ltd. Announces Achievement of Milestone Using J-Brain Cargo Technology for Neurodegenerative Disease in Research Collaboration with Alexion

JCR Pharmaceuticals (TSE:4552) Is Due To Pay A Dividend Of ¥10.00

JCR Pharmaceuticals Co., Ltd.(TSE:4552) dropped from FTSE All-World Index (USD)

JCR Pharmaceuticals Co., Ltd. to Report Fiscal Year 2024 Results on May 10, 2024

JCR Pharmaceuticals (TSE:4552) Has Affirmed Its Dividend Of ¥10.00

JCR Pharmaceuticals Co., Ltd. Announces Organizational and Personnel Changes

Now 22% overvalued

JCR Pharmaceuticals Co., Ltd. Presents Clinical Data on J-Brain Cargo®? to Deliver Medicines Across the Blood-Brain Barrier

JCR Pharmaceuticals Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024

Price target decreased by 10% to JP¥1,657

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

JCR Pharmaceuticals Co., Ltd. to Report Q3, 2024 Results on Jan 26, 2024

New major risk - Share price stability

JCR Pharmaceuticals Co., Ltd. Announces First Patient Dosed in a Global Phase I/II Clinical Trial of JR-441 for the Treatment of MPS IIIA

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

JCR Pharmaceuticals Co., Ltd. Declares Interim Dividend for the Fiscal Year Ending March 31, 2024, Payable on December 8, 2023; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

JCR Pharmaceuticals Co., Ltd. Announces 52-Week Interim Data from its Global Phase I/II Study of JR-171 in Individuals with Mucopolysaccharidosis Type I (MPS I)

Upcoming dividend of JP¥10.00 per share at 1.5% yield

Investor sentiment improves as stock rises 18%

PHC IVD and JCR Announce GROWJECTOR® Duo

JCR Pharmaceuticals Co., Ltd. to Report Q2, 2024 Results on Oct 25, 2023

JCR Pharmaceuticals Co., Ltd. Provides Consolidated Earnings Guidance for the Full Year Ending March 31, 2024

Consensus EPS estimates increase by 13%

First quarter 2024 earnings released: EPS: JP¥12.90 (vs JP¥11.05 in 1Q 2023)

Price target decreased by 7.4% to JP¥1,859

JCR Receives Approval to Start Global Phase I/II Clinical Trial for JR-441 for the Treatment of Mucopolysaccharidosis Type III A (MPS IIIA)

Jcr Pharmaceuticals Co., Ltd. Announces Executive Changes

JCR Pharmaceuticals Co., Ltd. Receives an Approval for Expanded Indication of Growject®? in Short Stature Due to SHOX-Deficiency

Full year 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates increase by 20%

JCR Pharmaceuticals Co., Ltd. Provides Consolidated Earnings Guidance for the Full Year Ending March 31, 2024

JCR Pharmaceuticals Co., Ltd. to Report Q1, 2024 Results on Jul 26, 2023

Consensus EPS estimates fall by 24%

Full year 2023 earnings: EPS and revenues miss analyst expectations

JCR Pharmaceuticals Co., Ltd. Announces Dividend for the Year Ended March 31, 2023, Payable on June 22, 2023

Investor sentiment deteriorates as stock falls 18%

Now 21% undervalued after recent price drop

Consensus revenue estimates fall by 17%

Upcoming dividend of JP¥10.00 per share at 1.3% yield

JCR Pharmaceuticals Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

JCR Pharmaceuticals Co., Ltd. to Present Phase I/II Clinical Data on JR-171

Third quarter 2023 earnings released: EPS: JP¥20.89 (vs JP¥29.79 in 3Q 2022)

U.S. Fda Grants Rare Pediatric Disease Designation for JCR Pharmaceuticals Co., Ltd. Jr-141 for Mpsii

JCR Pharmaceuticals Co., Ltd. Appoints Yoh Ito as Senior Corporate Officer

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

JCR Pharmaceuticals Announces Interim Dividend Payable on December 9, 2022; Provided Dividend Guidance for Fiscal 2023

Now 20% undervalued after recent price drop

JCR to Initiate Development of New Drug Candidate for Fucosidosis

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

JCR Pharmaceuticals Co., Ltd. Announces Interim Dividend on Retained Earnings, Payable on December 9, 2022

Price target decreased to JP¥2,861

Now 21% undervalued after recent price drop

Upcoming dividend of JP¥10.00 per share

Jcr Pharmaceuticals Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

JCR Pharmaceuticals Co., Ltd. Announces Update on Application for Manufacturing and Marketing Approval of JR-141 for Treatment of MPS II (Hunter Syndrome) in Brazil

First quarter 2023 earnings released: EPS: JP¥11.05 (vs JP¥12.39 in 1Q 2022)

JCR Pharmaceuticals Co., Ltd Files for Expanded Use GROWJECT for Short Stature Due to SHOX-Deficiency

JCR Pharmaceuticals Co., Ltd. Announces Executive Changes

JCR Pharmaceuticals Co., Ltd. Appoints Pascal Yoshida as Senior Director, Head of Medical Affairs Unit